$BMA

USP1047VAF42 Bond Analysis — Key Metrics

This article provides key metrics and an overview of the Banco Macro S.A. 6.75% bond (USP1047VAF42) maturing on November 4, 2026. It details the issuer, issue and maturity dates, outstanding amount, face value, minimum denomination, and coupon rate. The bond analysis is presented through TradingView, offering insights into the financial instrument and the issuing company.

Original reporting
Published Apr 23, 2026, 4:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 23, 2026, 4:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
USP1047VAF42 Bond Analysis — Key Metrics — source image
Decision brief

The 30-second read

$BMANeutralLow
01

Why it matters

The bond's stable coupon and issuer's credit profile suggest moderate risk, with limited short-term volatility.

02

Market read

The bond provides insight into regional credit conditions and investor appetite for fixed-income assets in emerging markets.

03

What to watch

Potential currency risk or macroeconomic shifts could impact bond performance beyond current assessments.

Timing: long-term

Background

Banco Macro S.A. is a prominent financial institution in Argentina, issuing bonds to finance operations.

Company-level read

Ticker impact

$BMANeutralMedium confidence
Context

Bond issuer: Banco Macro S.A.

Expected impact

Minimal immediate impact expected on the bond's price; slight appreciation possible if macroeconomic conditions remain stable.

Evidence & confidence

The bond's fixed coupon and stable issuer suggest limited short-term volatility, but broader market factors could influence its valuation.

Market effects

The bond's stability reflects positively on the financial sector's credit environment.

Limited regional impact due to the bond's localized issuer focus.

Minimal global relevance given the issuer's regional scope.

Counterpoint

The bond may be undervalued if macroeconomic conditions deteriorate, presenting a buying opportunity.

Key entities

  • Banco Macro S.A.

    A leading bank in Argentina with a diversified portfolio.

Related articles

$BMAMed

Banco Macro Announces Results for the Second Quarter of 2026

Banco Macro reported 2Q26 net income of Ps.206.8 billion, up 39% from the previous quarter and 4% year-over-year. Operating income before expenses was Ps.1.29 trillion, down 2% quarter-over-quarter but up 1% year-over-year. The bank's total financing increased 3% quarter-over-quarter but decreased 5% year-over-year. Banco Macro maintains strong solvency and liquidity ratios, with excess capital of Ps.4.1 trillion and liquid assets covering 74% of deposits.

$BMAHigh

Macro Bank Inc. (BMA): Financial results for Q2 2026

Macro Bank Inc. (BMA) furnished an SEC Form 6-K — earnings release. Yes o No x 2Q26 Earnings Release AUGUST 19TH, 2026 BANCO MACRO 2Q26 EARNINGS RELEASE 2 Index 01 Summary 02 Disclaimer 03 Results 04 Financial Assets 05 Public Sector Assets 06 Funding 07 Liquid Assets 08 Solvency 09 Asset Quality 10 2Q26 Snapshot 11 Relevant and Recent Events 12

$BMAMedAI 8/10

Banco Macro Q1 2026 Earnings Call Transcript - Banco Macro (NYSE:BMA)

Banco Macro reported Q1 2026 net income of 139.8 billion pesos, up 28% quarter-on-quarter and 131% year-on-year, according to the earnings call transcript. Operating income before expenses fell 3% vs. Q4 2025 but rose 15% year-on-year. The bank kept 2026 loan growth guidance at 42% nominal and deposit growth at 34% nominal, assuming 28% inflation. NPL ratio was 5.4% with ~110% coverage; cost of risk guidance is 5.5%–6%.

$BKRMed

Baker Hughes (BKR) Secures Order For 76 Gas Turbines

Baker Hughes (BKR) secured an order for 76 NovaLT™16 gas turbines from Dynamis Power Solutions, valued at 1.3 GW, for hypermobile power projects. The turbines are designed for rapid deployment in data centers and oil and gas operations, aligning with Baker Hughes' focus on distributed power and digital infrastructure. Analysts view this as part of the company's strategy for higher-margin, recurring revenue streams.

$AMGNLowAI 8/10

Evolocumab before PCI for acute MI improves LDL control

Amgen's evolocumab (Repatha) improved LDL control in acute MI patients by 1 year when administered early, but did not impact clinical outcomes vs. standard care, according to the AMUNDSEN trial presented at the European Society of Cardiology Congress and published in JAMA. 82% of patients on evolocumab met LDL targets vs. 40% on standard care alone.